Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O75521

UPID:
ECI2_HUMAN

ALTERNATIVE NAMES:
DRS-1; Delta(3),delta(2)-enoyl-CoA isomerase; Diazepam-binding inhibitor-related protein 1; Dodecenoyl-CoA isomerase; Hepatocellular carcinoma-associated antigen 88; Peroxisomal 3,2-trans-enoyl-CoA isomerase; Renal carcinoma antigen NY-REN-1

ALTERNATIVE UPACC:
O75521; Q5JYK5; Q5JYK7; Q7L124; Q8N0X0; Q9BUE9; Q9H0T9; Q9NQH1; Q9NYH7; Q9UN55

BACKGROUND:
The protein Enoyl-CoA delta isomerase 2, also referred to as Hepatocellular carcinoma-associated antigen 88 and Renal carcinoma antigen NY-REN-1 among other names, is essential for the isomerization of enoyl-CoA species in lipid metabolism. This enzyme efficiently converts 3-cis and 3-trans double bonds into the 2-trans configuration, favoring 3-trans substrates, which is a critical step in the beta-oxidation pathway.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Enoyl-CoA delta isomerase 2 offers a promising avenue for the development of novel therapeutic approaches. Its key role in the metabolism of unsaturated fatty acids positions it as a potential target in treating metabolic diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.